79074-45-6

Usage

Uses

Used in Flavor and Fragrance Industry:
2-(Bromomethyl)-3,5,6-trimethylpyrazine is used as a flavoring agent for its characteristic roasted, nutty, and cocoa-like aroma, adding depth and complexity to the taste and scent of food products such as meat, coffee, and chocolate-flavored goods.
Used in Food Products:
In the food industry, 2-(Bromomethyl)-3,5,6-trimethylpyrazine is used as an aroma enhancer to impart a rich, roasted flavor to a variety of products, improving the overall sensory experience for consumers.
Used in Industrial Manufacturing:
Beyond its applications in food, 2-(Bromomethyl)-3,5,6-trimethylpyrazine is also utilized in the manufacturing of various industrial products, where its unique properties may contribute to the development of new materials or processes.
Potential Use in Pharmaceuticals and Chemical Synthesis:
Given its chemical structure, 2-(Bromomethyl)-3,5,6-trimethylpyrazine may have potential applications in pharmaceuticals and chemical synthesis, although further research and development would be required to explore these possibilities.
Safety Considerations:
Due to its potentially hazardous nature, 2-(Bromomethyl)-3,5,6-trimethylpyrazine should be handled and stored with care, adhering to proper safety protocols to minimize risks associated with its use.

Upstream product

• 1124-11-4 Tetramethylpyrazine 
• 75907-74-3 2-Pyrazinemethanol,3,5,6-trimethyl 
• 79074-43-4 (3,5,6-trimethylpyrazin-2-yl)methyl acetate 
• 22978-83-2 2,3,5,6-tetramethylpyrazine mono N-oxide 
• 76494-51-4 Tetramethylpyrazine hydrochloride 

Downstream Products

• 947243-80-3 ethyl 4-[(3,5,6-trimethylpyrazin-2-yl)methoxy]benzoate 
• 1018438-90-8 (E)-ethyl 3-(3-methoxy-4-((3,5,6-trimethylpyrazin-2-yl)methoxy)phenyl)acrylate 
• 1018438-88-4 4-((3,5,6-trimethylpyrazine-2-yl)methoxyl)-3-methoxybenzoic acid methyl ester 
• 1018438-85-1 3-((3,5,6-trimethylpyrazine-2-yl)methoxyl)-4-methoxybenzoic acid ethyl ester 
• 1018438-83-9 4-((3,5,6-trimethylpyrazine-2-yl)methoxyl)-3,5-dimethoxybenzoic acid ethyl ester 
• 1018438-92-0 (E)-ethyl 3-(4-((3,5,6-trimethylpyrazin-2-yl)methoxy)phenyl)acrylate 
• 947243-92-7 ethyl 4-(trifluoromethyl)-2-[(3,5,6-trimethylpyrazin-2-yl)methoxy]benzoate 
• 1339947-03-3 (R)-(3,5,6-trimethylpyrazinyl)methyl 2-acetoxy-3-(3,4-diacetoxyphenyl)propanoate 
• 1339947-08-8 C₂₆H₃₂N₂O₈ 
• 1339947-09-9 C₂₉H₃₈N₂O₈ 
• 1339947-10-2 C₂₉H₃₈N₂O₈ 
• 1339946-94-9 C₁₇H₂₀N₂O₅ 
• 1339947-43-1 C₂₈H₃₀N₂O₇ 
• 1339947-45-3 C₂₁H₂₄N₂O₇ 

Relevant academic research and scientific papers

Intramolecular Diels-Alder reaction of pyrazines with an alkenyl side chain

Intramolecular Diels-Alder reaction of a series of pyrazines bearing a 5-membered-ω-alkene side chain in refluxing trifluoroacetic acid led to the formation of bridged tricyclic compounds. These cycloadducts underwent Retro Diels-Alder reaction in refluxing nitrobenzene to give original pyrazines.

Synthesis and antitumor evaluation of one novel tetramethylpyrazine-rhein derivative

To discover multi-effective and low toxic anticancer lead compound from traditional Chinese medicine prescription, we synthesized one novel tetramethylpyrazine-rhein derivative which was composed of two main antitumor ingredients of Huazhenghuisheng Pian. The design idea was enlightened by "combination principle" in drug discovery and "compatibility principle" in traditional Chinese medicine. Compound 5's antitumor activity was evaluated by human cancer cell Bel-7402, while the angiogenesis activity was valued by the chick chorioallantoic membrane (CAM) assays. The stability test was carried on artificial gastric juice and artificial intestinal juice; furthermore, compound 5's acute toxicity was evaluated in vivo. The results showed that compound 5 not only displayed antiproliferative activity on Bel-7402 cell (IC50 = 26.4 μM), but also dramatically suppressed normal angiogenesis in chick chorioallantoic membrane. And there was no hydrolysis or structural damage during 24 h in artificial digestive solution. The LD50 value of the compound 5 exceeded 3.2 g/kg by oral administration in mice.

Design, synthesis and anti-inflammatory evaluation of novel 5-benzylidene-3,4-dihalo-furan-2-one derivatives

Rosiglitazone has shown promising anti-inflammation effect. To develop preferable anti-inflammatory agents, twenty-two rosiglitazone analogs were synthesized and their anti-inflammatory activity was evaluated. Among these compounds, 6i and 6k displayed excellent inhibitory activities on the production of inflammatory mediators, including nitric oxide (NO), tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). Furthermore, 6i and 6k showed suppression effects on the nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways, and this suppression effects could be partially reversed by GW9662, which is a peroxisome proliferator-activated receptor γ (PPARγ) antagonist. Additionally, our docking results exhibited the well combination of 6i and 6k to PPARγ. So the anti-inflammation activity of 6i and 6k was due at least in part, to their interaction with PPARγ.

Proteomic analysis reveals the potential neuroprotective effects of tetramethylpyrazine dimer in neuro2a/APPswe cells

Alzheimer's disease (AD) is a common neurodegenerative disease characterized by pathological processes, including abnormal amyloid deposits and filament tangles, oxidative stress, neuroinflammation, and neurotrophic insufficiency, leading to chronic and prolonged neuronal loss and cognitive deficits. Tetramethylpyrazine (TMP) is one of the main active components of Ligusticum wallichii, a traditional Chinese medicine widely used for brain related disease. Here, we synthesized the TMP derivative tetramethylpyrazine dimer (DTMP), and evaluated the potential mechanisms underlying its potential neuroprotective effects using the murine neuron-like cells (N2a) transfected with the human "Swedish" mutant amyloid precursor protein (N2aAPP). ELISA results indicated that DTMP reduced the levels of Aβ1-40 and Aβ1-42 in N2aAPP. Then through proteomic analysis we identified a total of 208 differentially expressed proteins in N2aAPP cells compared to the wild-type N2a cells (N2aWT), including 144 increased and 64 decreased proteins. 449 differentially expressed proteins were revealed in N2aAPP cells on DTMP treatment with 69 increased and 380 decreased proteins. Bioinformatic analysis suggested that these proteins are enriched in mitochondrial function, the electronic transmission chain, ATP binding, oxidative phosphorylation, GTPase function, the transcriptional translation process, amino acid metabolism, nucleotide binding and others. Given the vital role of mitochondria in the pathogenesis of AD, we selected the electron transport chain pathway-related molecules to further validate these findings. Western-blot analysis demonstrated that DTMP significantly increased the levels of complex I (NDUAA), complex II (SDHB), complex III (UCRI), complex IV (COX5A) and complex V (ATP5A) in N2aAPP cells. The modulation of dysregulated proteins implicated in AD pathogenesis implies the pharmacological mechanisms of DTMP and its potential as a novel therapeutic choice in AD.

Novel Oxazolidinone Antibacterial Analogues with a Substituted Ligustrazine C-ring Unit

A series of novel oxazolidinone compounds with a substituted ligustrazine C-ring unit and different substituted groups at the C-5 side chain were designed and synthesized using linezolid as a lead and based on a scaffold hopping strategy. Their antibacterial and anti-inflammatory activities were evaluated. The results of in vitro antibacterial assays showed that all fourteen target compounds displayed potent activity against Gram-positive pathogens, particularly 8b, 13b, 14a, 14b, 15a, and 15b. Moreover, 14a and 14b exhibited significant inhibitory activities on the production of inflammatory mediators, including nitric oxide, interleukin-6, and tumor necrosis factor-alpha. Thus, these derivatives could serve as valuable candidates to develop anti-infective agents for the treatment of chronic wounds.

Flavone-ligustrazine compounds CH-X having selective anti-liver cancer effect, preparation method and applications thereof

The invention provides a preparation method of a class of flavone-ligustrazine series derivatives, and applications of the flavone-ligustrazine series derivatives in preparation of antitumor drugs. According to the invention, the compound has obvious inhi

Application of pyrazine compound in preparation of drugs

The invention relates to an application of a pyrazine compound in preparation of drugs. The drugs can be used for treating neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal dementia (FTD), vascular dementia, HIV-related dementia, multiple sclerosis, progressive lateral sclerosis, Friedreich's ataxia, neuropathic pain or glaucoma, inflammation, oxidative damage, and mitochondrial-related diseases.

Pyrazine compound and preparation method thereof

The invention relates to a pyrazine compound, a stereoisomer, a tautomer and a pharmaceutically acceptable salt thereof, wherein the pyrazine compound, the stereoisomer, the tautomer and the pharmaceutically acceptable salt thereof can treat Alzheimer's disease, Parkinson's disease, Huntington's disease, frontal temporal dementia (FTD), vascular dementia, HIV-related dementia, multiple sclerosis,progressive spinal cord lateral sclerosis, Friedel-Crafts ataxia, neuropathic pain or glaucoma and other neurodegenerative diseases, diabetes mellitus and related diabetic complications, inflammations, oxidative damage and mitochondria-related diseases.

Pyrazine derivative, and preparation method and medical use thereof

The present invention relates to a pyrazine derivative, and preparation method and medical use thereof. The pyrazine derivative can remove free radicals and suppress calcium overload and has cytoprotective effects, and can be used for the prevention and t

Ginkgolide B Derivative and Preparation Method And Use Thereof

Disclosed are a compound as shown in formula I or formula II or a pharmaceutically acceptable salt thereof, wherein R1 is selected from pyrazinyl or substituted pyrazinyl; and R2 is selected from pyrazinyl or substituted pyrazinyl, phenyl or substituted phenyl, alkyl or substituted alkyl.